3O - IGSF8 is an innate immune checkpoint and cancer immunotherapy target

Background

Loss of MHC-I antigen presentation is often associated with T cell excluded tumors, and represents a common mechanism of both primary and acquired resistance to immune checkpoint blockade (ICB) treatment. MHC-I normally acts as a marker of “self” and cells that lack MHC-I are recognized and killed by innate immunity. A major puzzle in cancer immunology remains as to how T cell excluded tumors with MHC-I antigen presentation defects evade innate immune killing.

Methods

Integrating functional genomics, big data, and artificial intelligence, we discovered that IGSF8 expressed on cancer cells is a conserved innate immune checkpoint. IGSF8 is normally expressed in neuronal tissues and is not essential in vitro or in vivo. However, knockout of IGSF8 in B16-F10 melanoma cell line decreased tumor growth in vivo. For clinical relevance of IGSF8 in tumor immunity, we analyzed genomics, transcriptomics, and clinical data from The Cancer Genome Atlas (TCGA). We developed an antibody (GV20-0251) against IGSF8 and tested its function to induce immune cell killing of cancer cells in vitro and inhibit tumor growth in vivo.

Results

IGSF8 has receptors on both natural killer (NK) cells and dendritic cells (DC) to strongly suppress NK cytotoxicity and antigen presentation. In many cancer types across TCGA, IGSF8 is frequently DNA copy number amplified and overexpressed, and IGSF8 expression is associated with low antigen presentation, low immune infiltration, and worse overall survival in patients with low MHC class I expression. We developed a cross-species reactive antibody against IGSF8 (GV20-0251) which blocks IGSF8 interaction with NK and DC. This antibody enhances NK killing of cancer cells in vitro and increases antigen presentation, NK-mediated cytotoxicity, and T cell signaling in vivo. In multiple syngeneic tumor models (B16-F10, CT26, LLC and EMT6), anti-IGSF8 shows single-agent efficacy and is synergistic with anti-PD1 in controlling tumor growth.

Conclusions

IGSF8 is a novel innate immune checkpoint and cancer immunotherapy target. Given the ability for anti-IGSF8 to activate innate immunity, a phase 1 study has been initiated to explore the IGSF8 inhibitor GV20-0251 in patients with advanced or metastatic solid tumors (NCT05669430).

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

GV20 Therapeutics.

Funding

GV20 Therapeutics.

Disclosure

K. Benhadji: Financial Interests, Personal, Officer: GV20 Therapeutics; Financial Interests, Personal, Stocks/Shares: Lilly; Other, Employment: Taiho Oncology. Y. Li, H. Liu, X. Xiao, H. Liu: Financial Interests, Personal, Full or part-time Employment, Stock options: GV20 Therapeutics. X. Wu, B. Xie, R. Zheng, Q.Yu: Financial Interests, Personal, Full or part-time Employment: GV20 Therapeutics. Q. Ding: Financial Interests, Personal, Full or part-time Employment, Stock Ownership: GV20 Therapeutics. C. Sheng: Financial Interests, Personal, Financially compensated role, Stock options: GV20 Therapeutics; Financial Interests, Personal, Full or part-time Employment: Novartis. X. Hu: Financial Interests, Personal, Officer, Stock Options: GV20 Therapeutics. X.S. Liu, T.Xiao: Financial Interests, Personal, Officer, Director, Stock ownership: GV20 Therapeutics.